HALIFAX, Nova Scotia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce that Chris Dobbin, President & CEO of Nova Leap, will present at the upcoming LD Micro Main Event XVII Conference to be held October 28-30, 2024 at the Luxe Sunset Boulevard in Los Angeles, CA.
The conference will bring together the most promising companies and top investors in microcap finance for three days of presentations and one-on-one meetings.
Mr. Dobbin will be presenting at the event by way of webcast on Tuesday, October 29, 2024 at 11:30 AM Eastern Time / (8:30 AM Pacific Time).
The presentation will be live streamed at the following link: LD Micro Main Event XVII 2024 | Sequire Events
The Company’s investor presentation, which will be referenced during the one-on-one meetings, will be accessible on the “Investors” page of the Nova Leap website located at:
https://novaleaphealth.com/corporate-presentation/.
About Nova Leap
Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #42 ranking on the 2021 Report on Business ranking of Canada’s Top Growing Companies, the #2 ranking on the 2020 Report on Business ranking of Canada’s Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 10 different U.S. states within the New England, Southeastern, South Central and Midwest regions as well as in Nova Scotia, Canada.
FORWARD LOOKING INFORMATION
Certain information in this press release may contain forward-looking statements, such as statements regarding the closing of the acquisition (including timing) and its expected impact on the Company, financing of the acquisition, and plans regarding future acquisitions and business growth. This information is based on current expectations and assumptions, including assumptions described elsewhere in this release and those concerning general economic and market conditions, the satisfaction of conditions to closing the acquisition, availability of working capital necessary for conducting Nova Leap’s operations, availability of desirable acquisition targets and financing to fund such acquisitions, and Nova Leap’s ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include staff and supply shortages, regulatory changes affecting the home care industry or government programs utilized by the Company, other unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management's current expectations and plans relating to the future, and these statements may not be appropriate for other purposes. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company's filings with the Canadian securities regulators, which filings are available at www.sedarplus.com.
CAUTIONARY STATEMENT
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
Last Trade: | C$0.25 |
Daily Volume: | 0 |
Market Cap: | C$21.550M |
November 26, 2024 November 07, 2024 October 29, 2024 October 15, 2024 September 23, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB